Neumora’s Depression Drug Fails to Meet Goals in Key Phase 3 Trial

Navacaprant showed no significant improvement over placebo in treating depression symptoms, leading to an 80% drop in the company’s stock price.

Neumora Therapeutics' experimental depression drug, navacaprant, did not achieve primary or secondary endpoints in its first Phase 3 trial, KOASTAL-1.
The trial showed no significant difference in depression scores or ability to experience pleasure when comparing navacaprant to a placebo after six weeks of treatment.
Female participants showed a stronger response to the drug compared to males, but the results were not statistically significant for the primary endpoint.
Following the disappointing data, Neumora’s stock price plummeted by over 80%, reaching an all-time low of approximately $2 per share.
The company plans further analysis of the trial results and will provide updates on navacaprant and its broader pipeline at the J.P. Morgan Healthcare Conference later this month.